 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ( Verrica ) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...

Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference

For the last three days, A.I.dvisor has detected that VRCA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Verrica Pharmaceuticals (VRCA, $5.92) Aroon Indicator entered a Downtrend on April 01, 2024.

Verrica Pharmaceuticals (VRCA, $5.92) Aroon Indicator entered a Downtrend on March 28, 2024.

This is a signal that VRCA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Verrica Pharmaceuticals (VRCA, $5.92) RSI Indicator left the overbought zone on March 28, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

Verrica Pharmaceuticals (VRCA, $5.65) price moved above its 50-day Moving Average on March 27, 2024

This price move could be a signal that VRCA may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Verrica Pharmaceuticals (VRCA, $5.65) price may drop as it broke higher Bollinger Band on Mar 27, 2024

We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s ( NASDAQ:VRCA ) business as it appears the...

Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA) Shift From Loss To Profit

NCE status provides a minimum of five years of regulatory exclusivity The Company's U.S. patents and pending patent applications related to YCANTH are projected to expire between 2034 and 2041...

Verrica Pharmaceuticals Announces that YCANTH  Receives New Chemical Entity Status and Orange Book Listing from the FDA

This indicator may be signaling that VRCA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Verrica Pharmaceuticals (VRCA, $5.06) entered Downtrend as Momentum indicator drops below 0 level on Mar 25, 2024

This is a Bullish indicator signaling VRCA's price could rise from here. Traders may explore going long the stock or buying call options...

Verrica Pharmaceuticals (VRCA, $5) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 22, 2024

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Volume (M)	125,739.00
52-Wk High	$7.76
52-Wk Low	$2.86

VRCA Verrica Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals